Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
3570
Trial Sponsor
Clinical Trial Start Date
2003
0Primary Completion Date
2003
0Study Completion Date
2003
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Prevention0
Intervention Type
Biological0
Intervention Name
Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®0
ACAM2000 Smallpox Vaccine0
Interventional Trial Phase
Phase 20
Official Name
The Effect of Dose on Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults With Previous Smallpox Vaccination0
Last Updated
August 13, 2018
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Quadruple0
Masked Party
Participant0
Outcomes Assessor0
Investigator0
Care Provider0
Study summary
The objective of this study is to determine the minimum dose of ACAM2000 needed to produce a cutaneous reaction in at least 90% of a population of healthy adults at least 28 years of age and previously vaccinated against smallpox.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
